PCVX VAXCYTE INC Product Launches 8-K Filing 2024 - VAX-31 Update Vaxcyte, Inc. announced positive results from its Phase 1/2 study of the VAX-31 vaccine for adults aged 50 and older, focusing on safety and immunogenicity.Get access to all SEC 8-K filings of the VAXCYTE INC